Level-Headed: Correlating Antiseizure Medication Drug Concentrations With Adverse Effects and Seizure Response.

Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy Hentschel M, Stoffel-Wagner B, Surges R, Surges R, Dolscheid-Pommerich RC. Epilepsia. 2024 Mar;65(3):620–629. doi:10.1111/epi.17873. Epub 2024 Jan 19 Objective: The aim of this study was to determine whether clinical efficacy and reported adverse effects (AEs) of the newer antiseizure medications (ASMs) brivaracetam (BRV), lacosamide (LCM), and perampanel (PER) have been associated with plasma levels of these ASMs. We also investigated whether plasma levels outside the reference range have led to dose adjustments. Methods: Plasma levels of 300 people with epilepsy (PWE) seen at our tertiary epilepsy center were determined by liquid chromatography-tandem mass spectrometry. PWE received BRV (n = 100), LCM (n = 100), or PER (n = 100), in most cases in polytherapy. Demographic and clinical data were retrospectively analyzed and related to plasma levels. The clinical efficacy of BRV, LCM, or PER was assessed retrospectively by comparing seizure frequency at the time of the current blood draw with seizure frequency at the time of first administration. AEs were also recorded and, if reported, compared retrospectively with the time of first administration. Results: No significant associations were found between plasma levels of BRV, LCM, or PER and seizure freedom (BRV, P = 1.000; LCM, P =.243; PER, P =.113) or responder status (BRV, P =.118; LCM, P =.478; PER, P =.069) at presentation. There was also no pattern between plasma levels and the occurrence of AEs. In the majority of cases, drug levels outside the reference ranges have not led to adjustments in the daily doses of BRV (93.5%), LCM (93.9%), or PER (89.1%). Significance: Plasma levels at a given time point did not allow conclusions to be drawn about seizure control or the occurrence of AEs. Our findings indicate that efficacy and tolerability cannot be predicted based on averaged data from a single plasma measurement due to high interindividual variability. Instead, individual reference values should be established when sufficient clinical data are available, in line with the 2008 International League Against Epilepsy position paper on therapeutic drug monitoring. [ABSTRACT FROM AUTHOR]